Evidence map›Paper›PMID 42777048›Full record

ArticleScience advances2026

Computational design of optimized and preferentially paired human TCR constant regions for improved T cell function.

Maria Radman, Astar Shamul-Raybi, Jake Parker, Sarel J Fleishman, Cyrille J Cohen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria RadmanThe Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.ORCID 0000-0003-4944-5222
Astar Shamul-RaybiThe Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.ORCID 0000-0002-5396-8643
Jake ParkerDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.
Sarel J FleishmanDepartment of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-3177-7560
Cyrille J CohenThe Laboratory of Tumor Immunology and Immunotherapy, The Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat Gan, Israel.ORCID 0000-0002-0619-5959

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell receptor (TCR) gene transfer is a promising approach for cancer immunotherapy, but its efficacy is limited by mispairing of TCR chains, which reduces surface expression and may generate off-target specificities. We applied the PROSS and FuncLib algorithms to engineer human TCR constant regions for improved stability and preferential pairing. After several screening rounds, we identified a variant, termed structurally enhanced TCR (SET), that exhibited markedly enhanced surface expression, functional avidity, and reduced mispairing. SET-expressing T cells secreted higher cytokine levels, displayed increased activation, and mediated superior cytotoxicity. Notably, SET demonstrated function in CD4

Indexed as

Receptors, Antigen, T-CellT-LymphocytesAlgorithmsAnimalsCD4-Positive T-LymphocytesHumansLymphocyte ActivationMiceXenograft Model Antitumor AssaysReceptors, Antigen, T-Cell

Identifiers

PMID42777048
PMCPMC13600159

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.